Clinical Trial

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A prospective, randomized, open-label, multicenter Phase 3 trial designed to compare the safety and efficacy of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable head and neck squamous cell carcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-14; most recent amendment 2024-05-16.
Status change: Not Yet Recruiting → Recruiting 2022-10-28
Trial Details
NCT Number NCT05582265
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Zhongshan People's Hospital, Guangdong, China, Shenzhen Sixth People's Hospital
Conditions Head and Neck Squamous Cell Carcinomas
Enrollment 537 participants
Start Date 2022-10-28
Primary Completion 2028-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2024-05-17